Skip to main content

Management of Hypercalcemia of Malignancy

Audiocasts - Supportive Care
Sonia Amin Thomas, PharmD, discusses the clinical significance of her Symptom Management Overview, “Management of Hypercalcemia of Malignancy.”
Related Items
Treatment With Morphine to Stop Rigors Associated With Rituximab and Antithymocyte Globulin
JHOP - August 2024 Vol 14, No 4 published on August 2, 2024 in Original Research, Chemotherapy, Adverse Events, Supportive Care
Evaluation of a Pharmacist-Driven High-Dose MTX Monitoring Protocol
JHOP - February 2024 Vol 14, No 1 published on February 23, 2024 in Original Research, Oncology Pharmacy Programs/Protocols, Adverse Events, Dose Escalation/Reduction, Supportive Care, Methotrexate
Clinical Role of Oncology Pharmacy Specialists in Oral Oncolytic Management in the Outpatient Hematology Clinic Setting
JHOP - October 2023 Vol 13, No 5 published on October 9, 2023 in Practical Issues in Pharmacy Management, Oncology Pharmacy Programs/Protocols, Oral Therapy, Chemotherapy, Supportive Care
Denosumab for First-Line Treatment of Hypercalcemia Associated with Malignancy: Retrospective Analysis
Katherine P. Morgan, PharmD, BCOP, CPP, Yujiao Sun, PharmD, Allison Deal, Jared Weiss, MD, Amber Cipriani, PharmD, BCOP
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in Original Research, Supportive Care, Immunotherapy, Adverse Events
Steroids plus Exercise Reduce Fatigue in Patients with Advanced Cancer
Corbin Davis
Web Exclusives published on February 24, 2020 in Supportive Care
Managing Bone Metastases Through a Multidisciplinary Approach
Meg Barbor, MPH
Web Exclusives published on December 11, 2018 in Supportive Care
A Taxing Consequence: Taxane Acute Pain Syndrome
Mark L. Zangardi, PharmD, BCOP
JHOP - June 2017 Vol 7, No 2 published on May 30, 2017 in Supportive Care, Symptom Management Overview
EGFR Inhibitor–Associated Papulopustular Rash
Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP
JHOP - March 2017 Vol 7, No 1 published on March 13, 2017 in Supportive Care
Barriers to Initiating Oral Oncolytics by Specialty Pharmacy or Payers Can Affect Patient Outcomes
Leslie Wyatt
Web Exclusives published on February 15, 2017 in Supportive Care
HER2 Receptor Antagonist–Associated Cardiotoxicity
Alison Palumbo, PharmD, MPH, BCOP, Joseph Bubalo, PharmD, BCPS, BCOP
JHOP - Sept 2016 Vol 6, No 3 published on August 22, 2016 in Supportive Care